Nurix Therapeutics, Inc. (NRIX) Market Cap & Valuation Ratios
Nurix Therapeutics, Inc. (NRIX) has a market cap of $2.8B, a trailing P/E of 10.0 and a price-to-sales ratio of 3.9, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-08-31 · read by EquiReason
NRIXNurix Therapeutics, Inc.Follow NRIX — free
—
Price chart with a free account
- Market cap
- 2.8B
- P/E TTM
- 10.0
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 26 Jan, in 94 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| NRIX | 2.8 | 10.0 | 2.9 | 6.9 | 13.4% | +739% | 41% | 102% |
| CELC | 3.2 | — | — | — | -6.0% | — | — | — |
| ELVN | 3.0 | — | — | — | -2.2% | — | — | -22% |
| TARS | 3.0 | — | 4.3 | — | 1.9% | +105% | -8% | -19% |
| DNLI | 2.9 | — | 619.4 | — | -14.9% | — | — | -71% |
| DYN | 2.9 | — | — | — | — | — | — | -262% |
| IRON | 2.9 | — | — | — | -6.9% | — | — | -48% |
| VKTX | 2.8 | — | — | — | -14.7% | — | — | -107% |
| VRDN | 2.5 | — | 26.8 | — | -13.2% | — | — | -48% |
| BEAM | 2.5 | — | 9.2 | — | — | +159% | -242% | -43% |
| ADMA | 2.4 | 15.3 | 4.8 | 10.6 | 4.9% | +8% | 44% | 37% |
| Median of these 10 | 15.3 | 9.2 | 10.6 | -6.5% | +105% | -8% | -48% |
P/E 10.0 vs. a peer median of 15.3; EV/Sales 2.9 vs. 9.2.
Growth vs. price
each dot a company · hover or tap for valuesNurix Therapeutics, Inc. — questions
- What is Nurix Therapeutics, Inc.'s market cap?
- $2.8B.
- What is Nurix Therapeutics, Inc.'s P/E ratio?
- 10.0 on trailing twelve-month earnings to 2026-08-31.
- What is Nurix Therapeutics, Inc.'s price-to-sales ratio?
- 3.9.
Every figure on this page comes from Nurix Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.